Trial
NCT05241613
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Accutar Biotechnology Inc
Collaborators
—
Condition
Metastatic Castration Resistant Prostate Cancer
Intervention
AC176
Why stopped
Subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-13